Premium
Myelodysplastic syndrome treatment with danazol and cis‐retinoic acid
Author(s) -
Letendre Louis,
Levitt Ralph,
Pierre Robert V.,
Schroeder Georgene,
Krook James A.,
Mailliard James E.,
Morton Roscoe F.,
Tschetter Loren K.
Publication year - 1995
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.2830480405
Subject(s) - danazol , cytopenia , medicine , refractory (planetary science) , retinoic acid , myelodysplastic syndromes , gastroenterology , endometriosis , biology , bone marrow , biochemistry , astrobiology , gene
We prospectively treated 46 patients with favorable myelodysplastic syndrome classified as refractory anemia (RA), refractory cytopenia (RC), or refractory anemia with ringed sideroblasts (RARS). These patients received one of two schedules of 13‐Cis‐Retinoic Acid (low dose 80 mg daily for 6 months vs. high dose 200 mg po daily for 3 months), or Danazol (800 mg po daily for 3 months), and were crossed over to the alternative drug in the absence of response or at progression. Using strict criteria of response we found little objective evidence of activity for either compound. Only two minor responses were seen among 22 patients treated with low dose 13‐CRA, 1 response among 20 cases that received high dose 13‐CRA, and 1 partial response and 1 minor response to Danazol among 34 cases. Neither 13‐Cis‐Retinoic Acid nor Danazol appear active enough in patients with favorable myelodysplastic syndrome to justify their use. © 1995 Wiley‐Liss, Inc.